Abstract
Although an extensive number of studies support the efficacy and tolerability of stimulants in the treatment of attention deficit/hyperactivity disorder (ADHD), in recent years, increasing concerns have been raised about their cardiovascular safety. We investigated whether a time domain analysis of heart rate variability (HRV) recordings in 24-h ECG under medication with stimulants yielded new information about therapy control in ADHD. We analysed the HRV parameter standard deviation of all normal sinus RR intervals over 24 h (SDNN), percentage of successive normal sinus RR intervals > 50 ms (pNN50) and root-mean-square of the successive normal sinus RR interval difference (rMSSD) from 23 children diagnosed by ADHD (19 boys and 4 girls), aged 10.5 ± 2.2 years, who were consecutively referred to our outpatient clinic for paediatric cardiology. Eleven children received medication with methylphenidate (MPH), while twelve children were initially examined without medication. Of these, eight probands were re-examined after therapy with MPH was established. Controls comprised 19 children (10 boys, 9 girls) from our Holter ECG data base without any cardiac or circulatory disease. Compared to healthy controls, the ADHD children with and without MPH treatment showed significantly higher mean heart rates (ADHD without MPH: 94.3 ± 2.2; ADHD with MPH: 90.5 ± 1.8, controls: 84.7 ± 1.8). pNN50 (ADHD without MPH: 6.5 ± 2.7; ADHD with MPH: 14.2 ± 6.9, controls: 21.5 ± 9.0) and rMSSD (ADHD without MPH: 26.1 ± 4.1; ADHD with MPH: 36.7 ± 8.3, controls: 44.5 ± 10.1) were lowest in ADHD children without MPH, middle in ADHD children with MPH and highest in controls. SDNN values were not significantly different. The hourly analysis shows highly significant reduced pNN50 and rMSSD values in untreated ADHD children between 5:00 pm and 6:00 am while the pattern approaches to levels of controls during MPH treatment. Data of this pilot study indicate a decreased vagal tone with significantly diminished HRV and higher heart rates in unmedicated ADHD children. These parameters of autonomic activation are ameliorated by MPH treatment. No evidence for negative impact of MPH on HRV was detected. Further studies will clarify a potential cardio-protective effect of MPH in ADHD.
Similar content being viewed by others
References
Al Haddad H, Laursen PB, Ahmaidi S, Buchheit M (2009) Nocturnal heart rate variability following supramaximal intermittent exercise. Int J Sports Physiol Perform 4:435–447
Arnsten AF (2009) Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 23(Suppl 1):33–41
Buchhorn R, Hulpke-Wette M, Nothroff J, Paul T (2002) Heart rate variability in infants with heart failure due to congenital heart disease: reversal of depressed heart rate variability by propranolol. Med Sci Monit 8:CR661-6
Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O’Duffy A, Connell FA, Ray WA (2011) ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365:1896–1904
Denchev P, Kaltman JR, Schoenbaum M, Vitiello B (2010) Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation 121:1329–1337
Faraone SV (2009) Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths. P T 34:678–694
Fei L, Anderson MH, Katritsis D, Sneddon J, Statters DJ, Malik M, Camm AJ (1994) Decreased heart rate variability in survivors of sudden cardiac death not associated with coronary artery disease. Br Heart J 71:16–21
Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T (2009) Sudden death and use of stimulant medications in youths. Am J Psychiatry 166:992–1001
Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV (2011) ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 306:2673–2683
Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, Becker J, Biederman J (2009) Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr 155:84–89
Huang YS, Tsai MH (2011) Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder Current Status of Knowledge. Cns Drugs 25:539–554
Imeraj L, Antrop I, Roeyers H, Deschepper E, Bal S, Deboutte D (2011) Diurnal variations in arousal: a naturalistic heart rate study in children with ADHD. Eur Child Adolesc Psychiatry 20:381–392
Jacob CP, Romanos J, Dempfle A, Heine M, Windemuth-Kieselbach C, Kruse A, Reif A, Walitza S, Romanos M, Strobel A, Brocke B, Schäfer H, Schmidtke A, Böning J, Lesch K (2007) Co-morbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorders in a tertiary referral center. Eur Arch Psychiatry Clin Neurosci 257:309–317
Leslie LK, Alexander ME, Trikalinos TA, Cohen JT, Parsons SK, Newburger JW (2008) Reexamining the emperor’s new clothes: ambiguities in current cardiac screening recommendations for youth with attention deficit hyperactivity disorder. Circ Cardiovasc Qual Outcomes 1:134–137
McCarthy S, Cranswick N, Potts L, Taylor E, Wong ICK (2009) Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 32:1089–1096
Negrao BL, Bipath P, van der Westhuizen D, Viljoen M (2011) Autonomic correlates at rest and during evoked attention in children with attention-deficit/hyperactivity disorder and effects of methylphenidate. Neuropsychobiology 63:82–91
Polanczyk G, Rohde LA (2007) Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 20:386–392
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942–948
Polderman TJ, Boomsma DI, Bartels M, Verhulst FC, Huizink AC (2010) A systematic review of prospective studies on attention problems and academic achievement. Acta Psychiatr Scand 122:271–284
Renner T, Gerlach M, Romanos M, Herrmann M, Reif A, Fallgatter A, Lesch K (2008) Neurobiologie des Aufmerksamkeitsdefizit-/Hyperaktivitätssyndroms. Nervenarzt 79:771–781
Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S (2011) Cardiovascular Events and Death in Children Exposed and Unexposed to ADHD Agents. Pediatrics 127:1102–1110
Schlander M, Trott GE, Schwarz O (2010) The health economics of attention deficit hyperactivity disorder in Germany. Part 1: Health care utilization and cost of illness. Nervenarzt 81:289–300
Schubert I, Köster I, Lehmkuhl G (2010) The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000–2007. Dtsch Arztebl Int 107:615–621
Singh RB, Weydahl A, Otsuka K, Watanabe Y, Yano S, Mori H, Ichimaru Y, Mitsutake G, Sato Y, Fanghong L, Zhao ZY, Kartik C, Gvozdjakova A (2001) Can nutrition influence circadian rhythm and heart rate variability? Biomed Pharmacother 55(Suppl 1):115s–124s
Singh RB, Kartik C, Otsuka K, Pella D, Pella J (2002) Brain-heart connection and the risk of heart attack. Biomed Pharmacother 56(Suppl 2):257s–265s
Task Force of the European Society of Cardiology and the North American society of Pacing (1996) Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 17:354–381
Taurines R, Schmitt J, Renner T, Conner AC, Warnke A, Romanos M (2010) Developmental comorbidity in attention-deficit/hyperactivity disorder. Atten Defic Hyperact Disord 2:267–289
Tonhajzerova I, Ondrejka I, Adamik P, Hruby R, Javorka M, Trunkvalterova Z, Mokra D, Javorka K (2009) Changes in the cardiac autonomic regulation in children with attention deficit hyperactivity disorder (ADHD). Indian J Med Res 130:44–50
Vaseghi M, Shivkumar K (2008) The role of the autonomic nervous system in sudden cardiac death. Prog Cardiovasc Dis 50:404–419
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Buchhorn, R., Conzelmann, A., Willaschek, C. et al. Heart rate variability and methylphenidate in children with ADHD. ADHD Atten Def Hyp Disord 4, 85–91 (2012). https://doi.org/10.1007/s12402-012-0072-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12402-012-0072-8